NCT07465224RecruitingPhase 2
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 15 Jan 2026
- Primary completion date
- 28 May 2027
- Lead sponsor
- Alnylam Pharmaceuticals
- Diseases
- Type 2 diabetes
- NCT number
- NCT07465224
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 24
- From 15 Jan 2026 to the primary completion date, 28 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
- Note: other protocol defined inclusion/exclusion criteria apply
Who the study is looking for
- Is an adult patient with a confirmed diagnosis of T2DM
- Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
- Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
- Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Chula Vista | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.